For millions of women navigating chronic pelvic pain, heavy bleeding, or unexplained infertility, the path to a diagnosis can be a years-long odyssey. Womb WatchAI, a Brooklyn-based biotech startup founded in 2024, is building an AI platform to shorten that journey by decoding the complex biological signatures of conditions that often go unseen. The company’s core bet is that a proprietary AI system, trained exclusively on female biological data, can recognize patterns and risks long before traditional clinical pathways catch up.
Its flagship product, Rhythm by Womb WatchAI, is an app and digital twin platform that allows users to track symptoms, nutrition, mood, and cycle data [rhythmbywombwatchai.com, retrieved 2026]. The underlying engine, the Bio-Intent Orchestration System (BIOS), is designed to analyze over 64,000 biological variables [WOMEN OF WEARABLES, retrieved 2024]. Founder and CTO Quanda Francis, who holds multiple patent-pending technologies, describes BIOS as a foundational intelligence layer built to personalize, predict, and optimize women’s health [WOMEN OF WEARABLES, retrieved 2024]. The company has filed six provisional patents and secured a USPTO trademark [Instagram, retrieved 2024].
The Architecture of a Digital Twin
At the heart of Womb WatchAI’s approach is a focus on creating a comprehensive digital biomarker profile. The platform integrates with Apple Health and Google Health, pulling in data across five stated areas: period tracking, nutrition, lab results, menstrual flow, and cancer surveillance [Womb WatchAI, retrieved 2024]. The company has developed six proprietary AI models trained solely on female data [Womb WatchAI, retrieved 2024]. This model-driven approach is intended to move beyond simple cycle tracking into predictive health, with a focus on conditions like endometriosis, polycystic ovary syndrome (PCOS), uterine fibroids, and adenomyosis [Womb WatchAI, retrieved 2024].
Early-stage traction is signaled through program affiliations rather than commercial deployments. It is a member of the NVIDIA Inception program and has backing from Google for Startups [NVIDIA Inception Program]. Founder Quanda Francis has stated she is personally funding the venture [Instagram, retrieved 2024]. In 2025, the company launched the "Her Health, Her Future" Research Fund [EIN Presswire].
Navigating a Crowded and Complex Field
| Company | Primary Focus | Key Differentiation |
|---|---|---|
| Womb WatchAI | AI-powered digital twin | Proprietary BIOS™ engine, 6 female-data-only models |
| Owaves | Circadian rhythm | Time-based lifestyle optimization |
| Crescent Health | Fertility & cycle tracking | Focus on conception and pregnancy planning |
| Chorus | Clinical research platform | Connects patients with clinical trials |
| MindMics | Cardiovascular analytics | Infrasonic hemodynamic sensing |
For Womb WatchAI, the path to clinical adoption and revenue remains an unanswered question. The company operates on a B2B2C model but has not yet publicly named healthcare system partners, insurer contracts, or validated clinical studies. The regulatory pathway for an AI system making health risk predictions is formidable; such software typically falls under FDA scrutiny as a Software as a Medical Device (SaMD). Furthermore, while the claim of a 56,000% organic growth rate circulates on social channels, it remains unverified by standard metrics [Instagram, retrieved 2024].
The Standard of Care Today
For the patient population Womb WatchAI aims to serve, the current standard of care is often fragmented and delayed. Diagnosis for conditions like endometriosis, which affects an estimated one in ten women, frequently takes seven to ten years. It relies on a slow process of symptom diaries, pelvic exams, imaging, and often definitive laparoscopic surgery. Womb WatchAI’s thesis is that continuous, AI-mediated analysis of multimodal personal data can surface objective patterns and risk flags much earlier, potentially guiding patients to the right specialist with a richer data profile in hand.